TRAVERE THERAPEUTICS, INC. Payments to Acquire Marketable Securities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Payments to Acquire Marketable Securities of $226.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $221.58M, a 244.23% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $5.05M.
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $167.93M, a 33.53% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $4.85M.
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2025 was $237.14M, a 88.57% increase from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2024 was $125.76M, a 71.67% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2023 was $443.94M, a 15.19% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2022 was $385.39M, a 29.55% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed | Payments to Acquire Marketable Securities 31 month | Payments to Acquire Marketable Securities 34 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $221.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $226.64M 10-Q · filed 2026-08-04 | $394.56M derived: sum of 3 quarters · filed 2026-08-04 | $399.41M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $5.05M 10-Q · filed 2026-05-04 | $172.98M derived: sum of 2 quarters · filed 2026-05-04 | $177.83M derived: sum of 3 quarters · filed 2026-05-04 | $242.20M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $167.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $172.77M derived: sum of 2 quarters · filed 2026-02-19 | $237.14M derived: sum of 3 quarters · filed 2026-08-04 | $237.14M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $4.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $69.22M derived: sum of 2 quarters · filed 2026-08-04 | $69.22M 10-Q · filed 2025-10-30 | $194.97M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $64.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $64.37M 10-Q · filed 2026-08-04 | $190.13M derived: sum of 3 quarters · filed 2026-08-04 | $190.13M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | $125.76M derived: sum of 2 quarters · filed 2026-05-04 | $125.76M derived: sum of 3 quarters · filed 2026-05-04 | $125.76M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $125.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $125.76M derived: sum of 2 quarters · filed 2026-02-19 | $125.76M derived: sum of 3 quarters · filed 2026-02-19 | $125.76M 10-K · filed 2026-02-19 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $62.65M derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $62.65M derived: sum of 3 quarters · filed 2026-02-19 | $218.28M derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-06 | $62.65M derived: sum of 2 quarters · filed 2026-02-19 | $218.28M derived: sum of 3 quarters · filed 2026-02-19 | $340.75M derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2023-12-31 | $62.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $218.28M derived: sum of 2 quarters · filed 2026-02-19 | $340.75M derived: sum of 3 quarters · filed 2026-02-19 | $443.94M 10-K · filed 2026-02-19 | |||
| 2023-09-30 | $155.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $278.10M derived: sum of 2 quarters · filed 2024-10-31 | $381.29M 10-Q · filed 2024-10-31 | $465.58M derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-06-30 | $122.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $225.66M 10-Q · filed 2024-08-01 | $309.94M derived: sum of 3 quarters · filed 2025-02-21 | $404.52M derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-03-31 | $103.19M 10-Q · filed 2024-05-06 | $187.47M derived: sum of 2 quarters · filed 2025-02-21 | $282.05M derived: sum of 3 quarters · filed 2025-02-21 | $462.30M derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2022-12-31 | $84.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $178.86M derived: sum of 2 quarters · filed 2025-02-21 | $359.11M derived: sum of 3 quarters · filed 2025-02-21 | $385.39M 10-K · filed 2025-02-21 | |||
| 2022-09-30 | $94.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $274.82M derived: sum of 2 quarters · filed 2023-11-07 | $301.10M 10-Q · filed 2023-11-07 | $346.04M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-06-30 | $180.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $206.53M 10-Q · filed 2023-08-03 | $251.46M derived: sum of 3 quarters · filed 2024-02-20 | $347.61M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-03-31 | $26.28M 10-Q · filed 2023-05-04 | $71.22M derived: sum of 2 quarters · filed 2024-02-20 | $167.36M derived: sum of 3 quarters · filed 2024-02-20 | $324.52M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2021-12-31 | $44.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $141.08M derived: sum of 2 quarters · filed 2024-02-20 | $298.24M derived: sum of 3 quarters · filed 2024-02-20 | $547.08M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | $96.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $253.31M derived: sum of 2 quarters · filed 2022-10-27 | $502.14M 10-Q · filed 2022-10-27 | ||||
| 2021-06-30 | $157.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $406.00M 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $248.84M 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | $214.96M 10-K · filed 2023-02-23 | ||||||
| 2019-12-31 | $223.71M 10-K · filed 2022-02-24 | ||||||
| 2018-12-31 | $331.35M 10-K · filed 2021-03-01 | ||||||
| 2017-12-31 | $102.42M 10-K · filed 2020-02-24 | ||||||
| 2016-12-31 | $184.11M 10-K · filed 2019-02-26 | ||||||
| 2015-12-31 | $198.53M 10-K · filed 2018-07-06 | ||||||
| 2014-12-31 | $10.15M 10-K · filed 2017-03-01 | $10.15M 10-K · filed 2015-03-11 | |||||
| 2014-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $4.89M 10-Q · filed 2014-08-14 | $5.58M derived: sum of 3 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | $2.67M 10-Q · filed 2014-05-15 | $3.36M derived: sum of 2 quarters · filed 2016-02-26 | |||||
| 2013-12-31 | $693.58K derived: 10-K 12 month − 10-Q/A 9 month · filed 2016-02-26 | $4.12M 10-K · filed 2016-02-26 | $4.12M 10-K · filed 2014-03-28 | $4.12M 10-K/A · filed 2015-07-09 | |||
| 2013-09-30 | $3.43M 10-Q/A · filed 2015-07-09 | $3.43M 10-Q/A · filed 2015-07-09 | |||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |